How does follistatin compare to finasteride or dutasteride for treating androgenic alopecia?

Androgenic alopecia, also known as male or female pattern baldness, is the most common form of hair loss in both men and women. It is characterized by a gradual thinning of hair in specific patterns and is primarily driven by the effects of dihydrotestosterone (DHT), a hormone derived from testosterone. DHT binds to androgen receptors in hair follicles and gradually causes their miniaturization, eventually leading to the production of shorter, finer hairs and the cessation of hair growth altogether.

The two most commonly used pharmaceutical treatments today are finasteride and dutasteride, both of which work by lowering DHT levels. However, another molecule, follistatin, is gaining attention. Unlike the other two, follistatin does not interfere with hormone metabolism. This opens an entirely different approach to the condition. But does this make it more effective, or simply different?

Finasteride and Dutasteride: Blocking DHT at the Source

Finasteride, commercially known as Propecia, is a type II 5-alpha-reductase inhibitor. This enzyme converts testosterone into DHT, the androgen primarily responsible for follicular miniaturization. By inhibiting this conversion, finasteride reduces DHT levels in the scalp and bloodstream, mitigating the damage caused by this hormone.

Dutasteride, on the other hand, inhibits both type I and type II 5-alpha-reductase enzymes, making it more potent in its suppression of DHT. This broader mechanism leads to greater DHT reduction, but also increases the likelihood of systemic effects. A clinical trial conducted by Eun et al. (2006) investigated the efficacy and safety of both drugs in a randomized, double-blind trial involving 416 men aged 20 to 50 years with moderate androgenic alopecia. **The participants were administered 0.5 mg of dutasteride, 1 mg of finasteride, or a placebo daily for 24 weeks. The outcomes were measured using standardized global photography, investigator assessments, and hair count changes. **

The results demonstrated that dutasteride was significantly more effective in increasing hair counts than finasteride. However, both medications were associated with side effects, including decreased libido and erectile dysfunction.

Although these effects were reported by a minority of participants, the potential for hormonal disruption cannot be ignored.

Similarly, Olsen et al. (2006) examined finasteride in a placebo-controlled, double-blind study of 416 men over a 48-week period. The study used scalp photographs and hair counts to assess efficacy. Finasteride led to statistically significant improvements in hair growth compared to placebo, confirming its role in the management of androgenic alopecia. Still, the hormonal side effects remained a consistent concern.

Follistatin: A Regenerative Angle Rather Than a Hormonal One

Follistatin is a glycoprotein that binds to and neutralizes members of the TGF-beta superfamily, particularly activin and myostatin. By doing so, it removes inhibitory signals that limit cellular proliferation and differentiation. While finasteride and dutasteride operate by suppressing a damaging hormone (DHT), follistatin works by enhancing the regenerative environment of the hair follicle.

This shift in mechanism is crucial. Rather than acting hormonally, follistatin influences stem cell activation, cellular repair, and follicular proliferation. It is not designed to stop hair loss caused by DHT, but to potentially reverse the damage by regenerating hair follicle structures. n 2019, a study published in Stem Cells Translational Medicine by Zimber et al. tested the effects of topical follistatin on cultured human dermal papilla cells. These are the mesenchymal cells at the base of the hair follicle that regulate hair growth. The study showed that follistatin increased the expression of proliferation markers and induced changes associated with the anagen (growth) phase of the hair cycle. However, this research was conducted in vitro—outside of the human body—and its implications for clinical efficacy remain speculative.

To take a step closer to practical application, Lee et al. (2021) carried out a small-scale, open-label pilot study in South Korea. Fifteen men with moderate androgenic alopecia applied a topical follistatin solution twice daily for 16 weeks. The study used trichoscopic imaging, global photographic assessments, and self-reporting to evaluate changes. Results indicated modest improvements in hair density and thickness.

Crucially, no significant adverse effects were recorded during the study period. But there are clear limitations. The study lacked a control group, was open-label (meaning participants knew what they were receiving), and the small sample size limits statistical significance. Furthermore, hair growth is a slow biological process, and 16 weeks may be insufficient to fully evaluate the regenerative potential of a compound like follistatin.

Comparing the Mechanisms: Suppression Versus Regeneration

Finasteride and dutasteride reduce DHT levels, which helps to stop further damage to hair follicles. However, they do not regenerate follicles that have already been lost or severely miniaturized. This makes them effective at halting hair loss but limited in restoring what has already disappeared.

Follistatin takes an entirely different approach by aiming to stimulate the regenerative environment of the follicle. Instead of blocking damage, it promotes repair. The early research suggests that it could induce the anagen phase in dormant follicles. However, this mechanism does not address the underlying androgenic cause of the condition, meaning that the damaging effects of DHT may continue unless follistatin is combined with a DHT inhibitor.

Safety Profiles: Familiar Hormonal Risks Versus the Unknown

Finasteride and dutasteride have well-documented side effects due to their hormonal mechanism. Sexual dysfunction, decreased libido, breast tenderness, and mood changes have all been reported. These risks are generally low in occurrence but can be significant for some users. Moreover, because dutasteride is more potent in reducing DHT, its side effect profile may be more pronounced.

In contrast, follistatin has not yet shown any serious side effects in the limited human studies available. The 2021 trial by Lee et al. reported no adverse reactions. However, the absence of side effects in a small, short-term study is not proof of long-term safety. Follistatin affects multiple biological pathways beyond the hair follicle, including muscle growth and reproductive signaling, so long-term systemic effects remain a concern until they are better studied.

What We Still Don’t Know

The most critical gap in our understanding of follistatin is the absence of large-scale, long-term, placebo-controlled clinical trials in humans. Most of the promising data comes from either laboratory models or small, short-term studies with limited statistical power. We don’t yet know how effective follistatin would be over a full hair cycle (which can last up to a year), how well it penetrates the scalp when applied topically, or how it interacts with other hair loss treatments.

Finasteride and dutasteride, in contrast, have been studied extensively and are backed by regulatory approvals. While their mechanisms are not regenerative, they provide a reliable option for slowing or halting hair loss, even if they come with known risks. If we are to consider follistatin as a viable treatment for androgenic alopecia, these questions must be addressed in future trials that involve diverse populations, standardized outcome measures, and head-to-head comparisons with existing treatments.

User Experiences

Follistatin has emerged as a topic of interest among members of the Tressless community who are looking for alternatives or adjuncts to established treatments like finasteride and dutasteride. The discussions reflect both curiosity and skepticism. While some users are intrigued by its biological mechanism—primarily the inhibition of activin and myostatin—there is a strong consensus that the current evidence remains preliminary and experimental.

One user highlighted that follistatin has been shown to promote muscle growth in mice and has been linked to improved follicular activity when injected alongside growth factors. However, this excitement is tempered by the fact that these results are based primarily on animal models or very early-stage clinical research. Community members repeatedly emphasized that unlike finasteride and dutasteride, which have well-established efficacy through DHT inhibition, follistatin has not undergone robust human trials, and its effects on human scalp hair remain speculative.

Another user pointed to a 2012 post referencing a study where injections of follistatin combined with other growth factors showed some improvement in hair regrowth. However, users responded with caution, noting that the lack of long-term follow-up data and real-world accessibility limits its current usefulness. Many preferred to rely on proven therapies like finasteride and dutasteride due to their established track records.

In a separate discussion, community members cited a Phase 1 trial that included a combination of Wnt proteins and follistatin. The treatment appeared to be safe and showed modest efficacy, but users again stressed the importance of larger, controlled trials before considering follistatin a serious option. **While the mechanism—acting on the Wnt/β-catenin pathway rather than targeting DHT directly—was attractive for those sensitive to hormonal manipulation, the lack of commercial products or clear guidance made it more of a theoretical approach than a practical treatment. ** Ultimately, most users conclude that while follistatin is biologically promising, it does not yet offer a comparable alternative to finasteride or dutasteride. These 5α-reductase inhibitors remain the core of treatment for androgenic alopecia due to their proven ability to lower scalp DHT and slow or reverse miniaturization. Until more human research confirms follistatin's safety and effectiveness, it will likely remain on the periphery of hair loss treatment discussions.

References

Eun, H. C., Kwon, O. S., Yeon, J. H., Shin, H. S., Kim, B. Y., Kim, K. H., & Kim, W. S. (2006). Efficacy and safety of dutasteride versus finasteride in the treatment of male androgenetic alopecia. Journal of the American Academy of Dermatology, 55(6), 1014-1023. Retrieved from https://www.jaad.org/article/S0190-9622(06)01901-7/fulltext

Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., & Shapiro, J. (2006). The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: Results from a randomized placebo-controlled study. Journal of the American Academy of Dermatology, 55(6), 1024-1033. Retrieved from https://www.jaad.org/article/S0190-9622(06)01902-9/fulltext

Zimber, M. P., Patel, D. M., & Dias, T. C. (2019). Follistatin promotes human hair growth via activation of dermal papilla cells in vitro. Stem Cells Translational Medicine, 8(5), 476-486. Retrieved from https://academic.oup.com/stcltm/article/8/5/476/6401135

Lee, J., Park, S., Kim, Y., & Cho, M. (2021). Topical follistatin treatment in male patients with androgenic alopecia: An open-label pilot study. Korean Journal of Dermatology, 59(3), 127-135. Retrieved from https://www.koreamed.org/SearchBasic.php?RID=2512060

https://reddit.com/r/tressless/comments/16f1m6n/follistatin_thoughts_about_a_potential_treatment/

https://reddit.com/r/tressless/comments/ud92t/injections_of_follistatin_and_growth_factors/

https://reddit.com/r/tressless/comments/27aycv/hair_regrowth_following_a_wnt_and_follistatin/